Drugs / 90Y-anti-Tac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00001249 | Dec 1989 → Oct 2000 | T-cell leukemia, primary cutaneous T-cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 90Y-anti-Tac | “We propose to administer 90Y-anti-Tac (10 mCi doses) to patients with Tac-expressing ATL” NCT00001249 ↗ |
| Known as | anti-Tac | “The study purpose is to evaluate the clinical response to multidose administration of anti-Tac monoclonal antibody conjugated with 10 mCi 90Y” NCT00001249 ↗ |
| Modality | Monoclonal antibody | “anti-Tac monoclonal antibody conjugated with 10 mCi 90Y” NCT00001249 ↗ |